# 1 Title

- 2 Large-scale clustering of longitudinal faecal calprotectin and C-reactive protein
- 3 profiles in inflammatory bowel disease

# 4 Short title

5 Longitudinal biomarker clustering in inflammatory bowel disease

# 6 Authors

7	Natha	n Constantine-Cooke <sup>*1,2</sup> , Marie Vibeke Vestergaard <sup>*3</sup> , Nikolas Plevris <sup>1,4</sup> , Karla		
8	Monte	rrubio-Gómez <sup>1,2</sup> , Clara Ramos Belinchón <sup>1,4</sup> , Solomon Ong <sup>4</sup> , Alexander T.		
9	Elford	<sup>4,5</sup> , Beatriz Gros <sup>4,6</sup> , Aleksejs Sazonovs <sup>3</sup> , Gareth-Rhys Jones <sup>4,7</sup> , Tine Jess <sup>†3,8</sup> ,		
10	Catali	na A. Vallejos <sup>† 2</sup> , and Charlie W. Lees <sup>† 1,3,4</sup>		
11		* Joint first authors,		
12		† Joint senior authors		
13	Affiliations			
14	1.	Centre for Genomic and Experimental Medicine, Institute of Genetics and		
15		Cancer, University of Edinburgh, Edinburgh, UK		
16	2.	MRC Human Genetics Unit, Institute of Genetics and Cancer, University of		
17		Edinburgh, Edinburgh, UK		
18	3.	Center for Molecular Prediction of Inflammatory Bowel Disease, PREDICT,		
19		Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark		
20	4.	Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK		
21	5.	Faculty of Medicine, The University of Melbourne, Melbourne, Australia		
22	6.	Reina Sofía University Hospital, Gastroenterology and Hepatology. IMIBIC.		
23		University of Cordoba. Cordoba, Spain		
24	7.	Centre for Inflammation Research, The Queen's Medical Research Institute,		
25		University of Edinburgh, Edinburgh, UK		
26	8.	Department of Gastroenterology & Hepatology, Aalborg University Hospital,		
27		Aalborg, Denmark		

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 28 Abstract

#### 29 Background

30 Crohn's disease (CD) and ulcerative colitis (UC) are highly heterogeneous, dynamic 31 and unpredictable, with a marked disconnect between symptoms and intestinal 32 inflammation. Attempts to classify inflammatory bowel disease (IBD) subphenotypes 33 to inform clinical decision making have been limited. We aimed to describe the latent 34 disease heterogeneity by modelling routinely collected faecal calprotectin (FC) and 35 CRP data, describing dynamic longitudinal inflammatory patterns in IBD.

#### 36 Methods

37 In this longitudinal study, we analysed patient-level post-diagnosis measurements of 38 FC and CRP in two European cohorts. Latent class mixed models were used to cluster 39 individuals with similar longitudinal profiles. Associations between cluster assignment 40 and baseline characteristics were quantified using multinomial logistic regression. 41 Differences in advanced therapy use across clusters were also explored. Finally, we 42 considered uncertainty in cluster assignments with respect to follow-up length and the 43 overlap between FC and CRP clusters. We included 1036 patients in the FC discovery 44 analysis (Lothian) with a total of 10545 FC observations (median 9 per subject, IQR 45 6–13), and 7880 patients in the replication (Denmark). The CRP discovery analysis 46 consisted of 1838 patients with 49364 measurements (median 20 per subject: IQR 47 10–36), with 10041 patients in the replication cohort.

#### 48 Findings

49 Eight distinct clusters of inflammatory behaviour over time were identified in the FC 50 and CRP analysis for the Scottish cohort. This model was then applied to the Danish 51 replication cohort, with similar patterns observed in both the Scottish and Danish 52 populations. The clusters, FC1-8 and CRP1-8, were ordered from the lowest 53 cumulative inflammatory burden to the highest. The clusters included groups with high 54 diagnostic levels of inflammation which rapidly normalised, groups where high 55 inflammation levels persisted throughout the full seven years of observation, and a 56 series of intermediates including delayed remitters and relapsing remitters.

57 CD and UC patients were unevenly distributed across the clusters. In UC, male sex 58 was associated with the poorest prognostic cluster (FC8). The use and timing of 59 advanced therapy was associated with cluster assignment, with the highest use of early advanced therapy in FC1. Of note, FC8 and CRP8 captured consistently high 60 61 patterns of inflammation despite a high proportion of patients receiving advanced 62 therapy, particularly for CD individuals. We observed that uncertainty in cluster 63 assignments was higher for individuals with short longitudinal follow-up, particularly 64 between clusters capturing similar earlier inflammation patterns. There was broadly 65 poor agreement between FC and CRP clusters in keeping with the need to monitor 66 both in clinical practice.

#### 67 Interpretation

Distinct patterns of inflammatory behaviour over time are evident in patients with IBD.
Cluster assignment is associated with disease type and both the use and timing of
advanced therapy. These data pave the way for a deeper understanding of disease

71 heterogeneity in IBD and enhanced patient stratification in the clinic.

## 72 Introduction

Inflammatory bowel disease (IBD), an umbrella term for Crohn's disease (CD), 73 74 ulcerative colitis (UC) and inflammatory bowel disease unclassified (IBDU), has a 75 prevalence of almost 1% in the UK.<sup>1,2</sup> IBD is characterised by chronic relapsing and remitting inflammation of the gastrointestinal (GI) tract that confers a host of 76 debilitating symptoms, negatively impacting guality of life.<sup>3,4</sup> Studies have clearly 77 demonstrated that uncontrolled GI tract inflammation increases the risk of disease 78 progression and complications including colorectal cancer.<sup>5</sup> stricturing/penetrating 79 complications, and surgery.<sup>6,7</sup> However, IBD is highly heterogeneous with respect to 80 81 symptoms, inflammatory burden, treatment response, and long-term outcomes.

82

83 Current IBD classification methods are mostly based on historic nomenclature which 84 utilise baseline phenotypic characteristics and do not take into account the dynamic 85 and unpredictable nature of the disease. Attempts at developing prediction tools to 86 identify high risk patients have been made but again use static clinical parameters, dismissing the changing nature of the disease.<sup>8</sup> Furthermore, they do not take into 87 88 account the influence of other factors, such as advanced therapy timing, on the 89 disease course. In the wake of the increasing prevalence of IBD and associated 90 healthcare burden.<sup>9</sup> new methods to characterise the dynamic disease course and 91 help identify at-risk individuals who require aggressive therapy with close monitoring 92 versus those that need less intense input are essential.

93

The original IBSEN studies provided the first data on the clinical course of patients with UC and CD during the first 10-years of diagnosis.<sup>10,11</sup> However, these data were predicated on predefined disease patterns, rather than being data driven, utilising symptoms alone. It is now widely accepted that there is a clear disconnect between inflammation and symptoms in IBD.<sup>12</sup> It is therefore imperative characterisations of disease course include objective parameters of inflammation.

100

101 C-reactive protein (CRP) and faecal calprotectin (FC) are well established tools for 102 monitoring patients with IBD, but are typically interpreted in terms of the most recent 103 measurement or short-term trends. Interrogation of long-term trends of inflammation 104 could greatly assist clinical decision making and improve prediction of future events.

105 Moreover, modelling inflammatory behaviour over time might be a key tool for 106 characterising the largely unexplained heterogeneity seen in IBD, and provide new 107 tools for disease sub-phenotyping beyond the current Montreal classification.<sup>13</sup>

108

In this study, we aimed to 1) identify groups of IBD patients with similar longitudinal patterns of inflammation, 2) determine if these groupings were associated with age, sex, IBD type, Montreal classification, or therapy, and 3) explore whether subjects with similar longitudinal FC profiles also share similar CRP profiles. To assess the robustness of our findings, we perform the analysis separately in two population-level cohorts, one covering the NHS Lothian health board in Scotland and one national-level registry in Denmark.

# 116 Methods

#### 117 Ethics

Usage of the Scottish dataset was approved by the local Caldicott Guardian (Project ID: CRD18002, registered NHS Lothian information asset #IAR-954). In Denmark, studies based on registry data alone are not required to obtain permission from the regional ethics committees as confirmed by The Central Denmark Region Committees on Health Research Ethics (legislation: 1–10–72-148-19). Patients or the public were not involved in the design, conduct, reporting or dissemination plans of our research.

#### 124 Study design

This was a cohort study carried out separately in two population-level cohorts, based
in Scotland and Denmark, respectively. Detailed definitions for each cohort are
provided in Supplementary Note 1.

128

In Scotland, patients with a confirmed diagnosis of IBD (Lennard-Jones criteria)<sup>14</sup> were followed up for a period of seven years from the date of diagnosis. Baseline phenotype data (sex, age at diagnosis, IBD type, date of diagnosis) were obtained from the Lothian IBD registry (LIBDR), a retrospective cohort of patients receiving IBD care in Lothian, Scotland. The LIBDR is estimated to have identified 94.3% of all IBD patients

in the area.<sup>1</sup> Using a population-level cohort reduces potential biases due to recruitment.<sup>15</sup> When available, additional phenotyping was extracted by the clinical team from electronic health records (TrakCare; InterSystems, Cambridge, MA). This includes smoking and Montreal classification for disease location, behaviour and extent, all recorded at the time of diagnosis. Data on prescribing of all advanced therapies, including start/stop dates, were extracted from TrakCare and NHS Lothian pharmacy databases. Primary care prescribing data were not available.

141

142 In Denmark, patients with IBD were identified from national health registries using a 143 methodology previously described by Agrawal et al.<sup>16</sup> Briefly, patients were required 144 to have at least two IBD-related hospital interactions within a period of two years. All 145 Danish residents are assigned a personal identification number which can be used to 146 link interactions across the healthcare system. Montreal classification and smoking 147 status were not available for the Danish cohort. However, this cohort had data on all 148 redeemed primary care prescriptions for corticosteroid and immunosuppressants, in 149 addition to advanced therapy prescribing.

#### 150 Inclusion/exclusion criteria

151 In the LIBDR, subjects were required to have a confirmed diagnosis of IBD at any age 152 and receive secondary care for their condition from the NHS Lothian health board. 153 Only subjects with a recorded date of IBD diagnosis between 2005 and 2019 were 154 included. The lower bound for this criteria was established as FC testing was not 155 routinely performed prior to this date. The upper bound ensured subjects had the 156 possibility of at least five years of follow-up at the time of data extraction. In the Danish 157 cohort, subjects were required to have a date of diagnosis between January 2015 and 158 September 2022. The lower bound was set based on when the Danish nationwide 159 Register of Laboratory Results for Research became nationwide. The upper bound 160 was set based on data availability.

161

162 In both cohorts, the following criteria were separately applied to longitudinal FC and 163 CRP measurements. Subjects were required to have a diagnostic measurement ( $\pm$ 164 three months of diagnosis, Figures <u>S1</u>, <u>S2</u>) and have a further two observations 165 available within the follow up periods of five and seven years for the Danish and LIBDR

166 cohorts respectively. If any biomarker measurements were observed within three 167 months prior to the recorded diagnosis date, measurements were realigned with 168 respect to diagnosis (<u>Figure S3</u>). Only non-censored observations were considered in 169 this calculation for FC. For CRP, this filtering was applied after preprocessing (see 170 "Longitudinal measurements and preprocessing" section), and subjects with constant

171 biomarker measurements over time were excluded.

#### 172 Statistical analysis

#### 173 Cohort description

- 174 Continuous variables were summarised as their median and interquartile range (IQR).
- 175 Categorical variables were summarised as counts and percentages.

#### 176 Longitudinal measurements and preprocessing

177 For the LIBDR, FC and CRP measurements were obtained from an extract by the local 178 biochemistry team describing tests recorded up to August 13, 2024. For each 179 individual, all measurements within seven years from diagnosis were considered. 180 Failed tests, for example due to contamination, were discarded. All FC tests were performed from stool samples using the same ELISA technology.<sup>17</sup> Due to limits of 181 182 detection, observations <20  $\mu$ g/g were recoded to 20  $\mu$ g/g whilst observations >1250 183  $\mu$ g/g were mapped to 1250  $\mu$ g/g. Such observations were treated as censored when 184 applying the inclusion exclusion criteria described above. CRP was measured from 185 blood samples; observations for which only an upper bound was available, e.g. <1 186 mg/L, were mapped to the corresponding upper bound.

187

Test results for the Danish data were obtained from subjects' local biochemistry teams. As national biochemistry data were only nationwide from 2015, only measurements within five years from the date of diagnosis were considered. Test results between January 2015 and September 2022 were considered. For FC, observations >1800µg/g were censored, whilst CRP observations <4mg/L were censored. As with the LIBDR, censored observations were recoded to their respective threshold.

194

195 To smooth out short-term fluctuations CRP measurements were further processed by 196 considering median values within fixed time intervals (Supplementary Note 2).

#### 197 Longitudinal biomarker clustering

198 The Scottish and Danish data were analysed separately. FC and CRP trajectories 199 (after log-transformation) were modelled separately using latent class mixed models (LCMMs).<sup>18</sup> enabling clustering of subjects that share similar longitudinal trajectories. 200 201 LCMM consists of two submodels: one which captures longitudinal behaviour, and one 202 which captures cluster assignment. Fixed effects for the longitudinal submodel were 203 specified as natural cubic splines. The intercept was used as a patient-level random 204 effect. The cluster assignment submodel used IBD type as a covariate. Model 205 definitions and hyper-parameter choices are shown in Supplementary Note 3.

206

207 As the number of clusters is not known a priori, the optimal model was found using a 208 grid search approach. We considered models with 2–10 clusters for both FC and CRP. <sup>19</sup> Akaike information criterion (AIC),<sup>19</sup> Bayesian information criterion (BIC), and visual 209 210 inspection of cluster trajectories were used to compare models with different 211 specifications and determine the most appropriate number of assumed clusters. The 212 optimal number of clusters was chosen based on the LIBDR dataset as it has a more 213 precise phenotyping (date of diagnosis, IBD type and additional information). The 214 chosen number of clusters was then applied when analysing the Danish cohort.

215

LCMM calculates, for each individual, the probability of being assigned to each cluster. In subsequent analyses, each individual was assigned to the cluster with the highest probability. The distribution of cluster assignment probabilities was used to assess uncertainty in these allocations with respect to follow-up length. This was defined as the time difference between diagnosis and the last available biomarker measurement (FC or CRP, depending on the analysis). For each cluster, the average probability of individual-specific probabilities of cluster assignment were reported.

223

To avoid displaying potentially identifiable individual-level data, exemplar trajectories within each cluster were visualised as aggregated trends, with measurements summarised as the median across six randomly selected individuals. For the LIBDR

analysis, clusters were ordered based on the area under the overall biomarker trendinferred for each cluster (a proxy for cumulative inflammatory burden). The clusters

- found in the Danish cohort were ordered manually to resemble similar trajectories.
- 230 Associations with respect to cluster assignments

To facilitate the interpretation of each cluster, we considered potential associations between cluster assignments and patient phenotypes. Violin plots and percentage bar plots were used as a visual summary when considering continuous (age) and discrete (sex, IBD type and, for LIBDR, additional phenotyping) covariates, respectively.

Multinomial logistic regression was used to quantify associations between cluster assignments and patient phenotypes (covariates). Multivariate models were considered, and the associated 95% confidence intervals are reported. Individuals with missing covariate values were excluded when fitting each model. As a sensitivity analysis, the analysis was repeated after excluding individuals with a low probability for cluster assignment (<0.5).

#### 242 Prescribing trends

To compare patterns of advanced therapy (AT) across clusters, the cumulative distribution of first-line advanced therapy use was calculated for both the Scottish and Danish cohorts. As primary care prescribing data were available for Danish subjects, patterns for systemic corticosteroid and immunomodulator use were also investigated. Results are reported stratified by IBD type (CD and UC only).

#### 248 Comparison between FC and CRP cluster assignments

For subjects meeting the criteria for both FC and CRP analyses, the relationship between FC and CRP cluster assignment was visualised using alluvial plots and sideby-side comparisons of mean cluster trajectories for the optimal models. Stratified results for CD and UC subjects are also reported.

253 Software

All analysis was performed in the R statistical software<sup>20</sup>; software/package versions are shown in Supplementary Note 4. Analytical reports for the LIBDR have been

- 256 generated using the Quarto scientific publishing system and are hosted online
- 257 (https://vallejosgroup.github.io/IBD-Inflammatory-Patterns/) with code used to perform
- the LIBDR and Danish analyses publicly available under an open source license
- 259 (https://github.com/VallejosGroup/IBD-Inflammatory-Patterns).
- 260 Role of the funding source
- 261 Funders were not involved in the study design, collection, analysis, or interpretation
- of the data, writing, or decision to submit the paper for publication.

### 263 Results

270

#### 264 Cohort derivation and description

In the Scottish cohort, 10545 FC and 49364 (9898 after preprocessing) CRP observations were available. In the Danish cohort, 67986 FC and 207141 (40648 after preprocessing) CRP observations were available. <u>Figure 1</u> outlines the derivation of the cohorts; <u>Table 1</u> describes key demographic factors. The distribution of logtransformed FC and CRP values is shown in <u>Figure S4</u>.



# Figure 1. Derivation of the study cohorts based on separate faecal calprotectin (FC) and C-reactive protein (CRP) inclusion/exclusion criteria. A 7-year follow-up period was used for LIBDR, a 5-year follow-up period was used for the Danish cohort.

	The Lothian IBD Registry		Danish national registry			
	FC analysis (n = 1036)	CRP analysis (n = 1838)	Overlap (n = 808)	FC analysis (n = 7880)	CRP analysis (n = 10041)	Overlap (n = 5685)
Age at diagnosis	33 (25–75)	37 (24–55)	32 (20–50)	33 (22–53)	38 (24–57)	32 (22-52)
Male sex	503 (48-6%)	956 (52.0%)	397 (49.1%)	3648 (46.3%)	4693 (46.7%)	2594 (45.6%)
IBD type						
Crohn's disease (CD)	544 (52-5%)	805 (43.8%)	451 (55-8%)	3931 (49-9%)	4415 (44.0%)	2954 (52.0%)
Ulcerative colitis (UC)	380 (36.7%)	847 (46-1%)	276 (34-2%)	3949 (50-1%)	5626 (56-0%)	2731 (48.0%)
IBDU	112 (10.8%)	186 (10-1%)	81 (10.0%)			
Baseline FC (µg/g)	740 (320– 1070)		760 (330– 1081)	574 (148- 1613)		652 (171- 1737)
FC observations	9 (6–13)		9 (6–14)	7 (4–11)		8 (5-12)
Baseline CRP (µg/mL)		8 (3–24)	8 (3–20)		12 (3-45)	20 (3-38)
Total unprocessed CRP observations		20 (10–36)	26 (14–36)		19 (9–32)	22 (12-34)
Total CRP observations after pre- processing		6 (4–7)	6 (5–7)		4 (3–5)	4 (3-5)
Advanced therapies (AT)						
AT within follow-up for CD	270 (49·6%)	374 (46·5%)		2108 (53-6%)	2246 (50-9%)	
AT within one year for CD	129 (23.7%)	167 (20.7%)		1517 (38.6%)	1549 (35.1%)	
AT within follow-up for UC	108 (28·4%)	85 (10.0%)		1293 (32•7%)	1702 (30.3%)	
AT within one year for UC	42 (11.1%)	35 (4.1%)		789 (20-0%)	978 (17-4%)	
Crohn's disease						
Montreal location						
L1	168 (30-9%)	249 (30.9%)	136 (30-2%)			

L2	200 (36-8%)	287 (35.7%)	157 (34-8%)
L3	169 (31-1%)	246 (30.6%)	153 (33-9%)
Missing	7 (1.3%)	23 (2.9%)	5 (1.1%)
Upper GI inflammation			
Present	77 (14-2%)	87 (10.8%)	68 (15.1%)
Not Present	467 (85.8·4%)	718 (89-2%)	383 (84-9%)
Montreal behaviour			
B1	443 (81-4%)	607 (75.4%)	364 (80.7%)
B2	63 (11.5%)	110 (13.7%)	54 (12.0%)
B3	28 (5.1%)	61 (7.6%)	25 (5.5%)
Missing	10 (1.8%)	27 (3-4%)	8 (1.8%)
Perianal disease			
Present	79 (14.5%)	113 (14.0%)	68 (15-1%)
Not Present	459 (84-4%)	673 (83.6%)	379 (84.0%)
Missing	6 (1.1%)	19 (2·4%)	4 (0.9%)
Smoking status			
Current or previously	166 (30.5%)	274 (34.0%)	138 (30.6%)
Never	352 (64.7%)	484 (60-1%)	293 (65.0%)
Missing	26 (4.8%)	47 (5.8%)	20 (4.4%)
Ulcerative colitis			
Montreal extent			
E1	50 (13·2%)	155 (18·3%)	27 (9.8%)
E2	155 (40.8%)	330 (39-0%)	111 (40·2%)
E3	170 (44.7%)	341 (40·3%)	133 (48.1%)

Missing	5 (1.3%)	21 (2·5%)	5 (1.8%)
Smoking status			
Current or previously	121 (31.8%)	336 (39.7%)	89 (32·2%)
Never	237 (62-4%)	444 (52·4%)	167 (60-5%)
Missing	22 (5.8%)	67 (7.9%)	20 (7·2%)

275 Table 1. Demographic and clinical data at diagnosis for subjects meeting the faecal calprotectin (FC) 276 or C-reactive protein (CRP) study inclusion criteria. Continuous data are presented as median and 277 interguartile range. Categorical data are presented as counts and percentages. Missingness is only 278 directly reported if values were missing. The column labelled as "Overlap" denotes subjects which met 279 the inclusion criteria for both FC and CRP modelling. Missing observations for upper gastrointestinal 280 inflammation were assumed to be "not present" (Supplementary Note 1). Missingness was not 281 inferred to be a value for any other variable. There are no IBDU diagnoses reported for the Danish 282 cohort as these were mapped to either CD or UC (Supplementary Note 1).

#### 283 Modelling of FC trajectories

For the LIBDR cohort, AIC suggested the 10-cluster model (Figure S5), whilst BIC suggested the 9-cluster model (Figure S6) was most appropriate (Table S1, Figure S7 (A)). However, the 8-cluster model was chosen as a parsimonious choice, as it captures the main observed longitudinal patterns without generating very small clusters (<50 individuals) which could be difficult to interpret.

289

290 Figure 2 (A) shows representative cluster profiles for the 8-cluster model in the Lothian 291 population, ordered from lowest (FC1) to highest (FC8) cumulative inflammatory 292 burden. FC2 (n=67; ~6%) represents low FC values throughout the whole observation 293 period. Instead, FC1 (n=140; ~14%), FC3 (n=157; ~15%), and FC7 (n=244; ~24%) 294 were characterised by initially high FC values (>250 µg/g) which decreased over time 295 at different rates. Whilst FC1 exhibited a sharp decrease within the first year, the 296 decrease was more gradual for FC3 and FC7, where FC was normalised (<250  $\mu$ g/g) 297 approximately around two and five years post diagnosis, respectively. Furthermore,

FC4 (n=103; ~10%), FC5 (n=67; ~6%) and FC6 (n=64; ~6%) captured relapsing and remitting patterns of gastrointestinal inflammation. Finally, FC8 (n=194; ~19%) represented individuals with consistently high FC values.

301

302 The 8-cluster model was then applied to the Danish data. Despite being a completely 303 independent analysis, using data from another healthcare system, and with a shorter 304 follow-up period, the shape of the cluster-specific trajectories largely matched those 305 found for the LIBDR cohort (Figure 2 (B)). In particular, the same rapid remitters (FC1), 306 delayed remitters (FC3 and FC7), and non-remitters (FC8) clusters were observed. 307 The most marked difference is within the relapsing-remitting clusters (FC4-6), which 308 may be partly explained by the smaller size of these clusters in the LIBDR cohort. The 309 proportion of individuals allocated to each cluster differed between cohorts. For 310 example, whilst FC2 represented  $\sim 6.5\%$  in the Scottish cohort, nearly one third of 311 patients (~30.1%) were assigned to FC2 in the Danish cohort.

#### 312 Associations with respect to FC cluster assignments

313 Associations with respect to age, sex and IBD type were considered in both cohorts 314 with the relapsing-remitting clusters (FC4–6) grouped for ease of comparison. Effect 315 sizes were largely consistent between both cohorts (Figures S8–S10). The effect of 316 age differed across clusters (Figure S8), but this may be partially due to differences in 317 treatment between younger and older individuals. Males were more likely to be 318 assigned to the clusters with the highest inflammatory burden, FC7 and FC8 (Figure 319 S9, S10 and S11). IBD type was associated with cluster assignments (Figure S12). 320 For example, FC1 (rapid remitters) was enriched by patients with CD in both cohorts 321 (62.9% in LIBDR and 63.0% in the Danish data vs 50.9% and 45.6% respectively 322 elsewhere). However, whilst the relapsing-remitting clusters (FC4-6) mostly consists 323 of individuals with UC in the Danish cohort (87.7%), this was not the case for LIBDR. 324

For the LIBDR cohort, a similar analysis was performed after stratifying by IBD type (UC and CD only) and considering additional phenotyping (Figures <u>S13–S19</u>). In most cases, effect sizes were not statistically significant (in some cases this was due to low counts and small cluster sizes). However, amongst patients with CD, those without upper GI inflammation were more likely to be assigned to the clusters with the lowest

inflammatory burden, FC1 or FC2 (2.4% and 3.03% L4 vs 18.1% elsewhere; Figure S13). Finally, UC patients with ulcerative proctitis were found to be less likely to be assigned to FC3 (2.44% E1 versus 14.2% elsewhere; Figure S19).

#### 333 FC cluster assignment and IBD therapy usage

334 In Scottish and Danish patients with CD, 23.7% and 38.6% received an advanced 335 therapy (AT) within one year of diagnosis, respectively (Table 1). This increased to 336 49.6% and 53.6% by the end of the observation period (seven and five years 337 respectively). For patients with UC, 11.1% and 20.0% received an AT within one year 338 of diagnosis, respectively for Scottish and Danish patients. This increased to 28.4% 339 and 32.7% by the end of the observation period. Overall AT rates and the distribution 340 of time to first AT were not homogeneous across clusters (Figure 3). For example, 341 whilst AT prescription rates in FC1 largely matched the overall FC cohort, prescriptions 342 were generally earlier in this cluster, especially in patients with CD. In both FC7 (the 343 very delayed remitting cluster) and in FC8 (the cluster with consistently high 344 inflammation levels), the cumulative AT rates for CD were high. By the end of follow-345 up in Scotland and Denmark, 55.1% and 80.9% were on AT in FC7 and 56.8% and 346 56.7% in FC8. However, early prescriptions of AT were noticeably lower than in other 347 clusters including FC1.

348

349 The detailed therapy data available from the Danish registries allows for a more 350 granular exploration of multiple lines of advanced therapy, immunosuppressant use 351 and courses of corticosteroids separately for CD (Figure S34) and UC (Figure S35). 352 In CD, FC1 is characterised by the early introduction of steroids, AT and 353 immunosuppressants, with therapy remaining remarkably stable throughout (no 354 additional lines of AT and no further courses of steroids). FC2 has the highest number 355 of patients not on AT after 1 (72.3%) and 5 years (62.5%). In FC3 (delayed remitters), 356 FC4 and FC6 (the two main relapsing remitting clusters for patients with CD), second, 357 third and fourth line AT prescriptions are noted along with multiple courses of 358 corticosteroids. These observations would be consistent with the challenges of treating 359 patients with IBD, where in some patients it takes time to find the right drug for the 360 right patient to induce deep remission, with multiple steroid courses used along the 361 way. A similar pattern is seen in FC7, where 25.5% had 3 or more different advanced

therapies, 23.7% had 5 or more steroid courses and 87.2% received an
immunomodulator within the five years. These are the largest numbers across all the
clusters, suggesting that multiple attempts are being made with different therapies to

365 control active disease with eventual success. In FC8, 29.3% and 13.1% of patients

had tried  $\geq 2$  and  $\geq 3$  different types of AT respectively, suggesting the persistently

- 367 elevated inflammation levels during follow-up are at least in part due to non-response368 to multiple lines of therapy.
- 369 In patients with UC, FC2 has the highest percentage of patients without treatment,
- 370 FC1 is relatively stable over time, and FC8 has the highest percentage of multiple 371 types of treatment.
- Surgical resections for patients with CD are shown in Figure S36. It is noteworthy that some of the patients assigned to a delayed remitting group (FC3 and FC7) were having surgical resections later in follow-up. Colectomy rates in UC were overall very low (Figure S37), but not evenly distributed with higher rates in those clusters with higher cumulative inflammatory burdens (10.5% in FC8 compared to 2.8% and 1.4% in FC1 and FC2).





380 Figure 2. Cluster trajectories obtained from LCMM assuming eight clusters fitted to FC data (log-381 transformed) in (A) the Lothian IBD Registry and (B) Danish national registry data. The blue and red 382 lines indicate predicted mean cluster profiles with 95% confidence intervals for the Lothian IBD 383 Registry and Danish data respectively. The yellow dotted lines indicate log(250µg/g). For visualisation 384 purposes, pseudo subject-specific trajectories have been generated by amalgamating observations 385 from randomly selected groups of six subjects. Clusters are ordered from lowest (FC1) to highest 386 (FC8) cumulative inflammatory burden in the Lothian data with Danish cluster labels chosen based on 387 visual similarity to the former clusters. Cluster sizes are shown as panel titles.

#### Modelling of CRP trajectories 388

389 AIC and BIC both suggested the 8-cluster model was the most appropriate (Table S2) for the LIBDR cohort. Visual inspection supported this finding as the 9-cluster model 390 391 did not identify new trajectories when compared to the 8-cluster model, producing two trajectories with consistently low CRP (Figure S20). In contrast, the 7-cluster model 392 393 (Figure S21) lacks one of the clinically interesting trajectories, characterised by an

initially elevated CRP which then decreases to slightly above biochemical remissionafter one year, when compared to the 8-cluster model.

396

397 Figure 4 (A) presents exemplar cluster profiles for the 8-cluster model. Over a third of 398 subjects (n=702: ~38%) were assigned to CRP1, defined by consistently low CRP (< 399 5µg/mL). CRP2 (n=225; ~12%) was characterised by high CRP at diagnosis which 400 rapidly decreased shortly thereafter remaining low. CRP3 (n=51; ~3%) and CRP4 401 (n=60; ~3%) are both small clusters with the former described by low CRP until the 402 last year of follow-up and the latter presenting low inflammation within the first year 403 before increasing until the third year where the inflammation then decreases again. 404 CRP5 (n=110; 6%) is characterised by elevated CRP at diagnosis which then 405 decreases gradually over time. CRP6 (n=434; 24%) consists of trajectories which are 406 elevated at diagnosis which then falls slightly for the first two years after diagnosis, 407 remaining elevated across the remaining duration of follow-up. CRP8 (n=172; 9%) is 408 consistently elevated and does not change over time. As in the FC analysis, the shape 409 of CRP clusters inferred for the LIBDR cohort was largely recapitulated when the 8-410 cluster model was applied to the Danish cohort (Figure 4 (B)).

#### 411 Associations with CRP cluster assignments

412 Figures S22–S24 visualise the distribution of age, sex and IBD type within each CRP 413 cluster. Results were largely consistent across the cohorts. Older patients were more 414 likely to be assigned to a CRP cluster with higher cumulative inflammatory burden 415 (Figure S22). IBD type was not evenly distributed among clusters (Figure S24), with 416 CRP1, CRP3, CRP4 and CRP7 enriched for UC patients (59.3%, 56.8%, 61.7% and 417 72.6% vs 32.3% elsewhere in LIBDR, with similar proportions for the Danish data. The 418 association plots for CD and UC disease sub-phenotypes and CRP cluster assignment 419 are shown in Figures <u>S25–S30</u>.

420

421 AT prescribing patterns in CRP clusters are shown in Figure S31.



Figure 3. FC cluster-specific cumulative distribution for first-line advanced therapy prescribing for Crohn's disease (red) and ulcerative colitis (teal) subjects in (A) the Lothian IBD Registry and (B) 425 national Danish registry data. Clusters are ordered from lowest (FC1) to highest (FC8) cumulative 426 inflammatory burden. The number of CD and UC subjects present in each cluster is displayed as 427 panel titles. Total advance therapy prescribing (as a percentage of the corresponding group) within 428 seven/five years from diagnosis is shown next to each distribution curve. Curves which would 429 describe fewer than ten subjects are not shown.



431 Figure 4. Cluster trajectories obtained from LCMM assuming eight clusters fitted to processed CRP 432 data (log-transformed) for subjects in (A) the Lothian IBD Registry and (B) national Danish registry 433 data. Blue and red lines indicate predicted mean cluster profiles with 95% confidence intervals. The 434 yellow dotted lines indicate log(5µg/mL). For visualisation purposes, pseudo subject-specific 435 trajectories have been generated by amalgamating observations from randomly selected groups of six 436 subjects. Clusters are ordered from lowest (CRP1) to highest (CRP8) cumulative inflammatory 437 burden. Cluster sizes are shown as panel titles.

It is made available under a



438

439 Figure 5. Exploration of cluster assignment uncertainty for A) faecal calprotectin (FC) and B) CRP

440 clusters in the Lothian IBD Registry cohort. LCMM assigns individuals to the cluster with the highest

441 estimated probability. For individuals assigned to a given cluster, bars show the average probability of

442 cluster assignment to each possible cluster. Results are stratified according to follow-up length,

443 defined as the time difference between diagnosis and the last available biomarker measurement (FC

- 444 or CRP for A) and B), respectively). Clusters are ordered from lowest (FC1 and CRP1) to highest
- 445 (FC8 and CRP8) cumulative inflammatory burden, with adjacent clusters coloured sequentially in the
- 446

plots for FC (black to yellow) and CRP (blue to yellow).

#### 447 Uncertainty in cluster assignments

448 The relationship between the uncertainty in cluster assignments and follow-up length 449 was explored for the LIBDR cohort. In the FC analysis, with the exception of FC2, 450 cluster assignments were on average more uncertain for those with a short follow-up 451 (Figure 5 (A)). This is particularly the case for FC clusters that share similar earlier 452 trends. For example, individuals assigned to FC1 (rapid remitters) had a low average 453 probability of being assigned to FC8 (non-remitters) and vice-versa, even for those 454 with a short follow-up. This is not the case for FC3 and FC6, both of which capture 455 similar FC trajectories within the first two years. Indeed, those assigned to FC6 with 456 less than two years of follow-up also have, on average, a high probability of being 457 assigned to FC3. On average, cluster assignments were less uncertain in the CRP 458 analysis, even for individuals with a short follow-up (Figure 5 (B)). This is expected as 459 CRP clusters are associated with more distinct early trajectories.

#### 460 Comparison of FC and CRP clustering

461 In the LIBDR cohort, all FC clusters were well represented amongst the 808 subjects 462 included in both analyses (*overlap sub-cohort*), but the proportion in CRP8 was low 463 (~27% of CRP8 was in the overlap sub-cohort vs ~46% elsewhere; Figure S32). As 464 shown in Figure 6 (A), there was low agreement between FC and CRP clustering in 465 the overlap sub-cohort (the same occurred in the Danish data, Figure S33). Whilst 466 most subjects in FC1 (71.6%) were also in CRP1 or CRP2, this relationship was not 467 mirrored as 81.2% of subjects in the latter two CRP clusters were assigned to 468 substantially different FC clusters. However, CRP8 did overlap with elevated FC as 469 the majority of subjects in this cluster (80.8%) were assigned to either FC7 or FC8.





471 Figure 6. Comparison between faecal calprotectin (FC) and processed CRP for models with chosen 472 specification (three NCS) assuming eight clusters for subjects in the Lothian IBD Registry cohort. 473 Results are reported based on the overlap cohort, consisting of 808 subjects included in both the FC 474 and CRP analysis. (A) all subjects; (B) Crohn's disease; and (C) ulcerative colitis. Each segment 475 denotes the size of the cluster whilst the alluvial segments connecting the nodes visualises the 476 number of subjects shared between clusters.

#### Discussion 477

478 We have characterised IBD behaviour using long-term longitudinal trends of objective 479 inflammatory markers routinely collected for clinical care. Our analysis has uncovered 480 eight clusters with distinct inflammatory profiles based on FC and CRP, respectively. 481 This was replicated in two independent cohorts, one based in Scotland (Lothian) and

one in Denmark (nationwide). Our data highlights the heterogeneity of the disease
course, and presents a novel approach for understanding real-world inflammatory
activity patterns in IBD patients. For the first time, we are capturing the dynamic nature
of the disease in a more biologically nuanced way than traditional behaviour endpoints
such as treatment escalation, surgery and "Montreal progression". This represents a
marked shift from the traditional symptom-based behaviour profiles exemplified by the
IBSEN cohorts over a decade ago.<sup>10,11</sup>

489

490 This study builds on our earlier proof-of-concept work, where we first demonstrated 491 the feasibility of using long-term individualised profiles of FC to cluster IBD patients 492 with CD.<sup>17</sup> In our previous analysis of Lothian patients, we identified four distinct FC 493 clusters: one cluster with persistently high FC (non-remitters) and three clusters with 494 different downward longitudinal trends. Here, we expand upon this by considering a 495 substantially larger Lothian IBD cohort (FC cohort, n=1036; CRP cohort, n=1838), with 496 longer follow-up, not excluding patients based on indicators of disease severity, and 497 also including patients with UC or IBDU. In addition, we modelled CRP. This has 498 generated results with greater representativeness across IBD phenotypes, uncovering 499 more granular structure with eight distinct FC clusters rather than four. Whilst the 500 modelling suggested further partitioning of the FC data was possible (Figure S5, 501 Figure S7 (A)), we selected the eight-cluster model as a parsimonious choice that 502 captured the key inflammatory patterns (Figure 2). Notably, the CRP data also 503 partitioned into eight distinct clusters. Together, the clusters broadly fall into four 504 patterns of inflammatory behaviour mirroring those recognised by gastroenterologists 505 managing IBD patients (i) rapid remitters (FC1 and CRP2), (ii) delayed remitters (FC3, 506 FC7 and CRP5), (iii) relapsing-remitters (FC4-6 and CRP4 and CRP7), and (iv) non-507 remitters (FC8 and CRP6 and CRP8). These classifications provide new insights into 508 the inflammatory course of IBD patients.

509

510 Critically, replication in two independent IBD cohorts demonstrates the robustness of 511 our findings, indicating that the longitudinal patterns described above characterise 512 inherent properties of the disease course. Both cohorts represent real-world IBD 513 populations with complementary properties. The Danish cohort is larger (n = 7880 and 514 n = 10041 for FC and CRP, respectively), has nation-wide coverage, and more 515 detailed treatment information (including primary care prescribing), but phenotyping is

516 more limited (e.g. no Montreal classification). Instead, LIBDR represents a single 517 Scottish health board and is more moderate in size (n = 1036 and n = 1838 for FC and 518 CRP, respectively), but has a longer longitudinal follow-up. Moreover, extensive data 519 curation provides more accurate diagnostic data and additional phenotyping, helping 520 to understand how the clusters relate to well-established IBD classifications.

521

522 We observed broadly poor agreement between FC and CRP clusters, although there 523 was overlap amongst those at the varying ends of the inflammatory spectrum with FC1 524 and FC2 correlating with CRP1 and CRP2 (rapid remitters with low cumulative 525 inflammatory burden), and FC7 and FC8 correlating with CRP6-8 (non-remitters with 526 high cumulative inflammatory burdens). Broadly though, the lack of overlap between 527 the two is not surprising. CRP is a marker of systemic inflammation, whilst FC is more 528 specific for detecting inflammation at a mucosal level. Hence, why both biomarkers 529 are complimentary when monitoring patients with IBD. Studies have also shown that a proportion of IBD patients will have lower CRP values at diagnosis,<sup>22</sup> as is seen in 530 531 CRP1 which is significantly enriched for UC cases.

532

533 We observed several important observations regarding cluster assignment. All IBD 534 subtypes featured in each cluster, but cluster assignment was unevenly distributed across IBD types (Figures <u>S12</u> and <u>S24</u>). In CD, although patients with L4 disease 535 536 were less represented in FC1 and FC2, there was no association with ileal versus 537 colonic disease location. Males were slightly overrepresented in the FC8 cluster, which 538 is characterised by persistently elevated values. Interestingly, in the recent SEXEII 539 study, they observed male patients with UC were more likely to have extensive colonic 540 involvement and abdominal surgery, which may account for this finding.<sup>23</sup> CRP cluster 541 membership was also associated with smoking and older age, with both more likely to 542 have higher inflammatory burdens.

543

544 Multiple lines of evidence, including the recent PROFILE study,<sup>24</sup> have clearly 545 demonstrated improved disease control and outcomes in Crohn's patients receiving 546 early AT. As such, we anticipated that the biggest driver of inflammatory patterns over 547 time would be AT and that this effect would be more pronounced in CD versus UC 548 especially given the era of our cohort. Indeed, rates of AT use were not homogenous 549 across clusters or IBD subtypes. Overall, in the FC LIBDR cohort, AT were used in

550 49.6% of CD patients of which 47.7% started AT in the first year. In FC1, similar rates 551 of AT were used for CD patients, however they were used earlier, suggesting their 552 positive benefit in rapidly inducing and maintaining remission. Rates of AT 553 prescriptions for patients with CD in FC8 (persistently high levels of inflammatory 554 behaviour) were similar, but started later in the disease course, which may have 555 negatively affected the ability to bring about remission of disease. This cluster may 556 also represent a more refractory group of patients, with a higher risk phenotype. Whilst 557 this may provide additional support for the use of early AT, a causal interpretation of 558 these effects is not possible in this study, which is based on observational data. 559 Additional work with alternative cohorts where treatment assignment is randomised is 560 planned.

561

562 Our study also highlights the importance of using a probabilistic approach to account 563 for uncertainty in cluster assignments. Indeed, we observed higher uncertainty for 564 subjects with a shorter longitudinal follow-up, particularly for FC clusters (Figure 5). In 565 such cases, we cannot confidently assign individuals to a specific cluster. Instead, 566 cluster assignment probabilities are sometimes evenly split across multiple clusters. 567 mostly between those with similar earlier behaviour and inflammatory burdens. This 568 effect is less prominent in CRP cluster assignments, partly due to the more distinct 569 early trajectories across CRP clusters. As such, we anticipate that a multivariate 570 approach which simultaneously considers other biomarkers of disease activity, such 571 as haemoglobin, albumin, and platelet count, may further increase the robustness of 572 cluster assignments. Such analysis may also consider pre-diagnostic biomarker 573 measurements, following the recent observations in Danish registry data,<sup>25</sup> as well as 574 metabolomics, genetics or microbiome data to inform cluster assignments.

575

576 Critically, this study is limited by the use of observational data. Beyond AT use, the 577 frequency and amount of biomarker measurements is likely to be higher for those with 578 a more severe disease, and very mild cases may be excluded from our cohort. 579 Moreover, FC and CRP clusters cannot be directly used in a prognostic way. Indeed, 580 future work is needed to assess associations between clusters and IBD related 581 complications (such as steroid use, hospitalisations and surgery) but also non-582 conventional complications related to a high cumulative inflammatory burden, such as 583 major cardiovascular adverse events, neuropsychiatric illness, and malignancy. Such

analyses will ultimately support the development of a low cost clinical support tool tohelp deliver precision medicine to patients with IBD.

586

587 Classifying patients by their inflammatory behaviour may better inform therapy 588 decisions, including timing of AT, as well as monitoring and follow-up requirements. 589 This is a paradigm shift in thinking about disease behaviour compared with the 590 previous symptom based profiles first reported by the IBSEN cohorts. Moreover, this 591 approach - rooted in data that is widely available in clinical settings<sup>26</sup> and probabilistic 592 modelling- paves the way for predictive analytics integrated into a clinical support tool 593 for population wide risk stratification and individual patient level prognostication and 594 treatment.

#### 595 Data sharing statement

- 596 As the data collected for this study has been derived from unconsented patient data,
- 597 it is not possible to share subject-level data with external entities. Detailed summary
- 598 level data is available online at https://vallejosgroup.github.io/IBD-Inflammatory-
- 599 <u>Patterns</u>. The code used to conduct the analysis is also publicly available

600 (<u>https://github.com/VallejosGroup/IBD-Inflammatory-Patterns</u>).

- Analyses performed on the DK cohort is based on data from the Danish National
  Health registries (https://sundhedsdatastyrelsen.dk). It is protected by the Danish Act
- 603 on Processing of Personal Data and access requires application to the Danish Data
- 604 Protection Agency and the Danish Health Data Authority. In addition, data handling
- 605 must be carried out by a Danish institution.

#### 606 Author contributions

607 CAV, CWL, and NCC were involved in conceptualising the study. CRB, SO, ATE, GRJ, 608 and NP curated the LIBDR data. NCC and CAV implemented computer code, tested 609 existing code components, and conducted the formal analysis and visualisation for the 610 LIBDR. TJ obtained funding for and built the Danish PREDICT data infrastructure on 611 which the Danish analyses were performed. MVV curated the Danish data and 612 conducted the validation analyses and visualization on the Danish data. The original 613 draft was written by NCC, NP, ATE, CMR, MVV, CWL and CAV with all authors

614 involved in reviewing and editing the manuscript. KMG, CWL, CAV, AS and TJ 615 provided supervisory support.

#### 616 Competing interests

617 NP has served as a speaker for Janssen, Takeda and Pfizer. BG has acted as 618 consultant to Galapagos and Abbvie and as speaker for Abbvie, Jansen, Takeda, 619 Pfizer and Galapagos. GRJ has served as a speaker for Takeda, Janssen, Abbvie, 620 Freshius and Ferring. TJ has served as a speaker and/or consultant for Ferring and 621 Pfizer. CWL has acted as a speaker and/or consultant to AbbVie, Janssen, Takeda, 622 Pfizer, Galapagos, GSK, Gilead, Vifor Pharma, Ferring, Dr Falk, BMS, Boehringer 623 Ingelheim, Eli Lilly, Merck, Novartis, Sandoz, Celltrion, Cellgene, Amgen, Samsung 624 Bioepis, Fresenius Kabi, Tillotts, Kuma Health, Trellus Health and Iterative Health. 625 None of the other authors report any conflicts of interest.

#### 626 Funding

627 CWL is funded by a UKRI (UK Research and Innovation) Future Leaders Fellowship 628 'Predicting outcomes in IBD' (MR/S034919/1). G-RJ is funded by a Wellcome Trust 629 Clinical Research Career Development Fellowship. NC-C was partially supported by 630 the Medical Research Council and The University of Edinburgh via a Precision 631 Medicine PhD studentship (MR/N013166/1). MVV, AS, and TJ are funded by a Center 632 of Excellence Grant (DNRF148) to TJ from the Danish National Research Foundation.

#### 633 Acknowledgements

634 This work uses data provided by patients and collected by the NHS as part of their

- 635 care and support. The Lothian component of this work has made use of the
- resources provided by the Edinburgh Compute and Data Facility (ECDF). The
- analysis of the Danish cohort was performed using the National Genome Center
- 638 platform.

# 639 References

640

1. Jones GR, Lyons M, Plevris N, et al. IBD prevalence in Lothian, Scotland, derived
by capture–recapture methodology. *Gut.* 2019;68(11):1953-1960.

- 643 doi:10.1136/gutjnl-2019-318936
- 644 2. Hamilton B, Green H, Heerasing N, et al. Incidence and prevalence of 645 inflammatory bowel disease in Devon. UK. Frontline Gastroenterol. 646 2021:12(6):461-470. doi:10.1136/flgastro-2019-101369
- 647 3. Cushing K, Higgins PDR. Management of Crohn disease: A review. JAMA. 648 2021;325(1):69. doi:10.1001/jama.2020.18936
- 649 4. Gros B. Kaplan GG. Ulcerative colitis in adults: A review. JAMA. 650 2023;330(10):951. doi:10.1001/jama.2023.15389
- 651 5. Zhou RW, Harpaz N, Itzkowitz SH, Parsons RE. Molecular mechanisms in colitis-652 associated colorectal cancer. Oncogenesis. 2023;12(1):48. doi:10.1038/s41389-653 023-00492-0
- 654 6. Kennedy NA, Jones GR, Plevris N, Patenden R, Arnott ID, Lees CW. Association 655 between level of fecal calprotectin and progression of Crohn's disease. Clin 656 Gastroenterol Hepatol. 2019;17(11):2269-2276.e4. doi:10.1016/j.cgh.2019.02.017
- 657 7. Plevris N, Fulforth J, Lyons M, et al. Normalization of fecal calprotectin within 12 658 months of diagnosis is associated with reduced risk of disease progression in 659 patients with Crohn's disease. Clin Gastroenterol Hepatol. 2021;19(9):1835-660 1844.e6. doi:10.1016/j.cgh.2020.08.022
- 661 8. Verstockt B. Noor NM. Marigorta UM. et al. Results of the Seventh Scientific 662 Workshop of ECCO: Precision medicine in IBD—Disease outcome and response 663 to therapy. J Crohns Colitis. 2021;15(9):1431-1442. doi:10.1093/ecco-jcc/jjab050
- 664 9. Alatab S, Sepanlou SG, Ikuta K, et al. The global, regional, and national burden of 665 inflammatory bowel disease in 195 countries and territories, 1990–2017: A 666 systematic analysis for the Global Burden of Disease Study 2017. Lancet 667 Gastroenterol Hepatol. 2020;5(1):17-30. doi:10.1016/S2468-1253(19)30333-4
- 668 Solberg IC, Vatn MH, Høie O, et al. Clinical course in Crohn's disease: 10. 669 Results of a Norwegian population-based ten-year follow-up study. Clin 670 Gastroenterol Hepatol. 2007;5(12):1430-1438. doi:10.1016/j.cgh.2007.09.002
- 671 Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years 11. 672 of ulcerative colitis: Results from a population-based inception cohort (IBSEN Studv). Scand J Gastroenterol. 2009;44(4):431-440. 673
- 674 doi:10.1080/00365520802600961
- 675 Peyrin-Biroulet L, Reinisch W, Colombel JF, et al. Clinical disease activity, C-12. 676 reactive protein normalisation and mucosal healing in Crohn's disease in the 677 SONIC trial. Gut. 2014;63(1):88-95. doi:10.1136/gutjnl-2013-304984
- 678 13. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, 679 molecular and serological classification of inflammatory bowel disease: Report of a 680 working party of the 2005 Montreal World Congress of Gastroenterology. Can J 681 Gastroenterol Hepatol. 2005;19:5A-36A. doi:10.1155/2005/269076
- 682 Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J 14. 683 Gastroenterol, 1989:24(sup170):2-6, doi:10.3109/00365528909091339
- 684 Sorlie P, Wei GS. Population-based cohort studies: Still relevant? J Am Coll 15. 685 Cardiol. 2011;58(19):2010-2013. doi:10.1016/j.jacc.2011.08.020
- Agrawal M, Christensen HS, Bøgsted M, Colombel JF, Jess T, Allin KH. The 686 16. 687 rising burden of inflammatory bowel disease in Denmark over two decades: A 688 nationwide cohort study. Gastroenterology. 2022;163(6):1547-1554.e5. 689 doi:10.1053/j.gastro.2022.07.062
- 690 17. Constantine-Cooke N, Monterrubio-Gómez K, Plevris N, et al. Longitudinal 691 fecal calprotectin profiles characterize disease course heterogeneity in Crohn's 692 disease. Clin Gastroenterol Hepatol. 2023;21(11):2918-2927.e6.

medRxiv preprint doi: https://doi.org/10.1101/2024.11.08.24316916; this version posted January 17, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- 693 doi:10.1016/j.cgh.2023.03.026 694 Proust-Lima C, Philipps V, Liquet B. Estimation of extended mixed models 18. 695 using latent classes and latent processes: The R package lcmm. J Stat Softw. 696 2017:78(2):1-56. doi:10.18637/iss.v078.i02 697 Stoica P, Selen Y. Model-order selection: A review of information criterion 19. 698 rules. IEEE Signal Process Mag. 2004;21(4):36-47. 699 doi:10.1109/MSP.2004.1311138 700 20. R Core Team. R: A Language and Environment for Statistical Computing. R 701 Foundation for Statistical Computing; 2022. https://www.R-project.org/ 702 Clough J, Colwill M, Poullis A, Pollok R, Patel K, Honap S. Biomarkers in 21. 703 inflammatory bowel disease: A practical guide. Ther Adv Gastroenterol. 704 2024;17:17562848241251600. doi:10.1177/17562848241251600 705 22. Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: A predictive factor 706 and marker of inflammation in inflammatory bowel disease. Results from a 707 prospective population-based study. Gut. 2008;57(11):1518-1523. 708 doi:10.1136/gut.2007.146357 709 23. Gargallo-Puyuelo CJ, Ricart E, Iglesias E, et al. Sex-related differences in the 710 phenotype and course of inflammatory bowel disease: SEXEII study of ENEIDA. 711 Clin Gastroenterol Hepatol. 2024;22(11):2280-2290. 712 doi:10.1016/j.cgh.2024.05.013 713 Noor NM, Lee JC, Bond S, et al. A biomarker-stratified comparison of top-24. 714 down versus accelerated step-up treatment strategies for patients with newly 715 diagnosed Crohn's disease (PROFILE): A multicentre, open-label randomised 716 controlled trial. Lancet Gastroenterol Hepatol. 2024;9(5):415-427. 717 doi:10.1016/S2468-1253(24)00034-7 718 Vestergaard MV, Allin KH, Poulsen GJ, Lee JC, Jess T. Characterizing the 25. 719 pre-clinical phase of inflammatory bowel disease. Cell Rep Med. 720 2023;4(11):101263. doi:10.1016/j.xcrm.2023.101263 721 Markowetz F. All models are wrong and yours are useless: Making clinical 26.
- 722 prediction models impactful for patients. Npi Precis Oncol. 2024;8(1):54. 723 doi:10.1038/s41698-024-00553-6

#### Supplemental display items 724

#### Table of contents 725

#### Supplemental figures 726

- 727 Figure S1. Distribution of observation times for diagnostic FC •
- 728 Figure S2. Distribution of observation times for diagnostic CRP •
- 729 Figure S3. Illustration of how biomarker (faecal calprotectin or CRP)

730 observation times were adjusted based on time of diagnostic biomarker

731 observation

732	•	Figure S4. Distribution of diagnostic biomarker measurements across the
733		LIBDR study cohort
734	•	Figure S5. Cluster trajectories obtained from LCMM assuming ten clusters
735		fitted to FC LIBDR data
736	•	Figure S6. Cluster trajectories obtained from LCMM assuming nine clusters
737		fitted to FC LIBDR data
738	•	Figure S7. Alluvial plot visualising cluster assignment for the LIBDR cohort as
739		the number of assumed clusters increases
740	•	Associations with FC cluster membership
741		• <u>Figure S8</u> . Age
742		• <u>Figure S9</u> Sex
743		<ul> <li>Figure S10. IBD type</li> </ul>
744		<ul> <li>Figure S11. Smoking for CD subjects</li> </ul>
745		<ul> <li>Figure S12. Montreal location for CD subjects</li> </ul>
746		<ul> <li>Figure S13. L4 for CD subjects</li> </ul>
747		<ul> <li>Figure S14. Montreal behaviour for CD subjects</li> </ul>
748		<ul> <li>Figure S15. Perianal disease for CD subjects</li> </ul>
749		<ul> <li>Figure S16. Smoking for UC subjects</li> </ul>
750		<ul> <li>Figure S17. Montreal extent for UC subjects</li> </ul>
751		<ul> <li>Figure S18. Sex for UC subjects</li> </ul>
752		<ul> <li>Figure S19. Sex for CD subjects</li> </ul>
753	•	Figure S20. Cluster trajectories obtained from model assuming nine clusters
754		fitted to CRP LIBDR data
755	•	Figure S21. Cluster trajectories obtained from model assuming seven clusters
756		fitted to CRP LIBDR data
757	•	Associations with CRP cluster membership
758		• <u>Figure S22</u> . Age
759		• <u>Figure S23</u> . Sex
760		<ul> <li><u>Figure S24</u>. IBD type</li> </ul>
761		<ul> <li>Figure S25. Smoking for CD subjects</li> </ul>
762		<ul> <li>Figure S26. Montreal location for CD subjects</li> </ul>
763		<ul> <li>Figure S27. L4 for CD subjects</li> </ul>
764		<ul> <li>Figure S28. Montreal behaviour for CD subjects</li> </ul>
765		<ul> <li>Figure S29. Smoking for UC subjects</li> </ul>

766		• Figure S30. Montreal extent for UC subjects
767	•	Figure S31. Time to first-line advanced therapy by CRP cluster assignment
768	•	Figure S32. Proportion of individuals included in the overlap cohort by FC and
769		CRP cluster assignment
770	•	Figure S33. Comparison between FC and CRP cluster assignment in the

- 771 Danish cohort.
- Supplemental tables 772

~ ~

- Table S1. Model statistics for models fitted to FC data 773
- 774 Table S2. Model statistics for models fitted to CRP data



#### Supplemental figures 775

776

777 Figure S1. Distribution of observation times for diagnostic faecal calprotectin (FC) relative to reported

778 date of diagnosis for (A) the Lothian IBD registry cohort and (B) the Danish national registry cohort.

779 Stratified by FC cluster assignment. Diagnostic FC was defined as the first FC test within ±90 days of diagnosis.



782 Figure S2. Distribution of observation times for diagnostic C-reactive protein (CRP) relative to 783 reported date of diagnosis for (A) the Lothian IBD registry cohort and (B) the Danish national registry 784 cohort. Stratified by CRP cluster assignment. Diagnostic CRP was defined as the first CRP test within 785 ±90 days of diagnosis.

#### Scenario 1:

First biomarker measurement within 90 days of reported date of diagnosis is before diagnosis



Biomarker observations are re-timed by the same amount so the first observation now corresponds to diagnosis

#### Scenario 2:

First biomarker measurement within 90 days of reported date of diagnosis is after diagnosis



Biomarker observations are not re-timed

786



Figure S4. Distribution of diagnostic biomarker measurements across the LIBDR study conort. (A)
 faecal calprotectin after applying a logarithmic transformation; (B) pre-processed (grouped into time
 intervals with the median used for multiple measurements) CRP after logarithmic transformation.



795 Figure S5. Cluster trajectories obtained from LCMM assuming ten clusters fitted to faecal calprotectin 796 data in the Lothian IBD Registry. Red lines indicate predicted mean cluster profiles with 95% 797 confidence intervals. Dotted horizontal lines indicate log(250µg/g). For visualisation purposes, pseudo 798 subject-specific trajectories have been generated by amalgamating observations from groups of six 799 subjects.



800

801 Figure S6. Cluster trajectories obtained from LCMM assuming nine clusters fitted to faecal 802 calprotectin data in the Lothian IBD Registry. Red lines indicate predicted mean cluster profiles with 803 95% confidence intervals. Dotted horizontal lines indicate log(250µg/g). For visualisation purposes,




Figure S7. Alluvial plot demonstrating how cluster assignment changes for the Lothian IBD registry
cohort as the number of assumed clusters increases for the chosen models for (A) faecal calprotectin
and (B) C-reactive protein. The clusters found by the 8-cluster models are labelled.





811 Figure S8. For each FC cluster, violin plots show the distribution of age at diagnosis across subjects, 812 highlighting median and interguartile ranges for (A) the Lothian IBD Registry and (B) Danish national 813 registry data. (C) Forest plot showing the estimated effect sizes and associated 95% confidence 814 intervals for age in a multinomial logistic regression model that uses FC cluster assignment as 815 outcome. Subjects with a posterior probability of belonging to their assigned cluster greater than 0.5 816 were considered in addition to all subjects in the cohort. Effect sizes are with respect to the reference 817 cluster (in this case FC1). The multivariate model includes age, sex and IBD type as covariates. The 818 dashed vertical lines are used as a reference to indicate no effect.



820 Figure S9. For each FC cluster, barplots show the proportion of individuals with female and male sex. 821 The dashed horizontal line represents overall proportions for (A) the Lothian IBD Registry and (B) 822 Danish national registry data. (C) Forest plot showing the estimated effect sizes and associated 95% 823 confidence intervals for male sex versus females (baseline category) in a multinomial logistic 824 regression model that uses FC cluster assignment as outcome. Subjects with a posterior probability of 825 belonging to their assigned cluster greater than 0.5 were considered in addition to all subjects in the 826 cohort. In (C), effect sizes are with respect to the reference cluster (in this case FC1). The multivariate 827 model includes age, sex and IBD type as covariates. The dashed vertical line is used as a reference 828 to indicate no effect.







840

841 Figure S11. Ulcerative colitis subjects only. For each FC cluster, barplots show the proportion of 842 individuals with female and male sex. The dashed horizontal line represents overall proportions for 843 (A) the Lothian IBD Registry and (B) Danish national registry data. (C) Forest plot showing the 844 estimated effect sizes and associated 95% confidence intervals for male sex versus females (baseline 845 category) in a multinomial logistic regression model that uses FC cluster assignment as outcome. 846 Subjects with a posterior probability of belonging to their assigned cluster greater than 0.5 were 847 considered in addition to all subjects in the cohort. In (C), effect sizes are with respect to the 848 reference cluster (in this case FC1). The multivariate model includes age, sex and IBD type as 849 covariates. The dashed vertical lines are used as a reference to indicate no effect.





850

- 852 ulcerative colitis and IBDU respectively in the Lothian IBD Registry. (B) Forest plot showing the 853 estimated effect sizes and associated 95% confidence intervals for IBD type in the Lothian IBD
- 854 Registry: ulcerative colitis and IBDU versus Crohn's disease (baseline category) in a multinomial
- 855 logistic regression model that uses FC cluster assignment as outcome. (C) For each FC cluster,
- 856 panels show the proportion of individuals with Crohn's disease and ulcerative colitis respectively in the
- 857 Danish cohort. (D) Forest plot showing the estimated effect sizes and associated 95% confidence 858 intervals for IBD type in the Danish cohort: ulcerative colitis versus Crohn's disease (baseline
  - 42

859 category) in a multinomial logistic regression model that uses FC cluster assignment as outcome. In 860 the Danish cohort, subjects were not assigned a subtype of "IBDU". Instead, they were assigned 861 either Crohn's disease or ulcerative colitis. Subjects with a posterior probability of belonging to their 862 assigned cluster greater than 0.5 were considered in addition to all subjects in the cohort. In (A) and 863 (C), the dashed horizontal line represents overall proportions across the FC cohorts. In (B) and (D), 864 effect sizes are with respect to the reference cluster (in this case FC1). In both cases, the multivariate 865 model includes age, sex and IBD type as covariates. The dashed vertical lines are used as a 866 reference to indicate no effect.



- 867
- 868
- Figure S13. Crohn's disease patients in the Lothian IBD Registry only. (A) For each FC cluster, panels
  show the proportion of individuals with smoking behaviour recorded as "no" (no and never) and "yes"
  (current or previously smoked) at diagnosis respectively. The dashed horizontal line represents
- 872 overall proportions across the entire FC cohort. (B) Forest plot showing the estimated effect sizes and
- 873 associated 95% confidence intervals for smoking: yes versus no (baseline category) in a multinomial

874 logistic regression model that uses FC cluster assignment as outcome. Subjects with a posterior
875 probability of belonging to their assigned cluster greater than 0.5 were considered in addition to all
876 subjects in the cohort, Effect sizes are with respect to the reference cluster (in this case FC1). The
877 multivariate model includes age, sex, smoking, Montreal location (L1, L2, L3), upper gastrointestinal
878 inflammation (L4), perianal disease (yes, no) and Montreal behaviour (B1, B2/B3) as covariates. The
879 dashed vertical lines are used as a reference to indicate no effect.



880

881 Figure S14. Crohn's disease patients in the Lothian IBD Registry only. (A) For each FC cluster, panels 882 show the proportion of individuals with Montreal Location recorded as L1, L2 and L3 respectively. The 883 dashed horizontal line represents overall proportions across the entire FC cohort. (B) Forest plot 884 showing the estimated effect sizes and associated 95% confidence intervals for Montreal Location: L2 885 and L3 versus L1 (baseline category) in a multinomial logistic regression model that uses FC cluster 886 assignment as outcome. Subjects with a posterior probability of belonging to their assigned cluster 887 greater than 0.5 were considered in addition to all subjects in the cohort. Effect sizes are with respect 888 to the reference cluster (in this case FC4). The multivariate model includes age, sex, smoking, 889 Montreal location (L1, L2, L3), upper gastrointestinal inflammation (L4), perianal disease (yes, no) and 890 Montreal behaviour (B1, B2/B3) as covariates. The dashed vertical lines are used as a reference to 891 indicate no effect.





892

893 Figure S15. Crohn's disease patients in the Lothian IBD Registry only. (A) For each FC cluster, panels 894 show the proportion of individuals with Montreal L4 (upper gastrointestinal inflammation), recorded as 895 present or non present. The dashed horizontal line represents overall proportions across the entire FC 896 cohort. (B) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for 897 L4: present versus not present (baseline category) in a multinomial logistic regression model that uses 898 FC cluster assignment as outcome. Subjects with a posterior probability of belonging to their assigned 899 cluster greater than 0.5 were considered in addition to all subjects in the cohort. Effect sizes are with 900 respect to the reference cluster (in this case FC1). The multivariate model includes age, sex, smoking, 901 Montreal location (L1, L2, L3), upper gastrointestinal inflammation (L4), perianal disease (yes, no) and 902 Montreal behaviour (B1, B2/B3) as covariates. The dashed vertical lines are used as a reference to 903 indicate no effect.



904

905 Figure S16. Crohn's disease patients in the Lothian IBD Registry only. (A) For each FC cluster, panels 906 show the proportion of individuals with Montreal behaviour recorded as B1 or B2/B3 respectively. The 907 dashed horizontal line represents overall proportions across the entire FC cohort. (B) Forest plot 908 showing the estimated effect sizes and associated 95% confidence intervals for Montreal behaviour: 909 B2/B3 versus B1 (baseline category) in a multinomial logistic regression model that uses FC cluster 910 assignment as outcome. Subjects with a posterior probability of belonging to their assigned cluster 911 greater than 0.5 were considered in addition to all subjects in the cohort. Effect sizes are with respect 912 to the reference cluster (in this case FC4). The multivariate model includes age, sex, smoking, 913 Montreal location (L1, L2, L3), upper gastrointestinal inflammation (L4), perianal disease (yes, no) and 914 Montreal behaviour (B1, B2/B3) as covariates. The dashed vertical lines are used as a reference to 915 indicate no effect.



916

917 Figure S17. Crohn's disease patients in the Lothian IBD Registry only. (A) For each FC cluster, panels 918 show the proportion of individuals with perianal disease recorded as present or not present. The 919 dashed horizontal line represents overall proportions across the entire FC cohort. (B) Forest plot 920 showing the estimated effect sizes and associated 95% confidence intervals for perianal disease: 921 present versus not present (baseline category) in a multinomial logistic regression model that uses FC 922 cluster assignment as outcome. Subjects with a posterior probability of belonging to their assigned 923 cluster greater than 0.5 were considered in addition to all subjects in the cohort. Effect sizes are with 924 respect to the reference cluster (in this case FC1). The multivariate model includes age, sex, smoking, 925 Montreal location (L1, L2, L3), upper gastrointestinal inflammation (L4), perianal disease (yes, no) and 926 Montreal behaviour (B1, B2/B3) as covariates. The dashed vertical lines are used as a reference to 927 indicate no effect.



- 928
- 929

930 Figure S18. Ulcerative colitis patients in the Lothian IBD Registry only. (A) For each FC cluster, 931 panels show the proportion of individuals with smoking behaviour recorded as "no" (no and never) and 932 "yes" (current or previously smoked) at diagnosis respectively. The dashed horizontal line represents 933 overall proportions across the entire FC cohort. (B) Forest plot showing the estimated effect sizes and 934 associated 95% confidence intervals for smoking: yes versus no (baseline category) in a multinomial 935 logistic regression model that uses FC cluster assignment as outcome. Subjects with a posterior 936 probability of belonging to their assigned cluster greater than 0.5 were considered in addition to all 937 subjects in the cohort. Effect sizes are with respect to the reference cluster (in this case FC1). The 938 multivariate model includes age, sex, smoking and Montreal extent (E1, E2, E3). The dashed vertical 939 lines are used as a reference to indicate no effect.



940

941 Figure S19. Ulcerative colitis patients in the Lothian IBD Registry only. (A) For each cluster, panels 942 show the proportion of individuals with Montreal extent recorded as E1, E2 and E3 respectively. The 943 dashed horizontal line represents overall proportions across the entire FC cohort. (B) Forest plot 944 showing the estimated effect sizes and associated 95% confidence intervals for Montreal extent: E2 945 and E3 versus E1 (baseline category) in a multinomial logistic regression model that uses FC cluster 946 assignment as outcome. Subjects with a posterior probability of belonging to their assigned cluster 947 greater than 0.5 were considered in addition to all subjects in the cohort. Effect sizes are with respect 948 to the reference cluster (in this case FC1). The multivariate model includes age, sex, smoking and 949 Montreal extent (E1, E2, E3). The dashed vertical lines are used as a reference to indicate no effect.



951 Figure S20. Cluster trajectories obtained from LCMM assuming nine clusters fitted to C-reactive 952 protein data in the Lothian IBD Registry. Red lines indicate predicted mean cluster profiles with 95% 953 confidence intervals. Dotted horizontal lines indicate log(5µg/mL). For visualisation purposes, pseudo 954 subject-specific trajectories have been generated by amalgamating observations from groups of six 955 subjects.





957 Figure S21. Cluster trajectories obtained from LCMM assuming seven clusters fitted to C-reactive 958 protein data in the Lothian IBD Registry. Red lines indicate predicted mean cluster profiles with 95% 959 confidence intervals. Dotted horizontal lines indicate log(5µg/mL). For visualisation purposes, pseudo 960 subject-specific trajectories have been generated by amalgamating observations from groups of six 961 subjects.



962

963 Figure S22. For each CRP cluster, violin plots show the distribution of age at diagnosis across 964 subjects, highlighting median and interguartile ranges for (A) the Lothian IBD Registry and (B) Danish 965 national registry data. (C) Forest plot showing the estimated effect sizes and associated 95% 966 confidence intervals for age in a multinomial logistic regression model that uses CRP cluster 967 assignment as outcome. Subjects with a posterior probability of belonging to their assigned cluster 968 greater than 0.5 were considered in addition to all subjects in the cohort. Effect sizes are with respect 969 to the reference cluster (in this case CRP1). The multivariate model includes age, sex and IBD type

#### 970

#### as covariates. The dashed vertical lines are used as a reference to indicate no effect.



972 Figure S23. For each CRP cluster, barplots show the proportion of individuals with female and male 973 sex. The dashed horizontal line represents overall proportions for (A) the Lothian IBD Registry and 974 (B) Danish national registry data. (C) Forest plot showing the estimated effect sizes and associated 975 95% confidence intervals for male sex versus females (baseline category) in a multinomial logistic 976 regression model that uses CRP cluster assignment as outcome. Subjects with a posterior probability 977 of belonging to their assigned cluster greater than 0.5 were considered in addition to all subjects in the 978 cohort. In (C), effect sizes are with respect to the reference cluster (in this case CRP1). The 979 multivariate model includes age, sex and IBD type as covariates. The dashed vertical line is used as a 980 reference to indicate no effect.



981

982 Figure S24. (A) For each CRP cluster, panels show the proportion of individuals with Crohn's disease, 983 ulcerative colitis and IBDU respectively. The dashed horizontal line represents overall proportions 984 across the entire CRP cohort. (B) Forest plot showing the estimated effect sizes and associated 95% 985 confidence intervals for IBD type: ulcerative colitis and IBDU versus Crohn's disease (baseline 986 category) in a multinomial logistic regression model that uses CRP cluster assignment as outcome. 987 (C) For each FC cluster, panels show the proportion of individuals with Crohn's disease and ulcerative 988 colitis respectively in the Danish cohort. (D) Forest plot showing the estimated effect sizes and 989 associated 95% confidence intervals for IBD type in the Danish cohort: ulcerative colitis versus 990 Crohn's disease (baseline category) in a multinomial logistic regression model that uses FC cluster

991 assignment as outcome. In the Danish cohort, subjects were not assigned a subtype of "IBDU". 992 Instead, they were assigned either Crohn's disease or ulcerative colitis. Subjects with a posterior 993 probability of belonging to their assigned cluster greater than 0.5 were considered in addition to all 994 subjects in the cohort. Effect sizes are with respect to the reference cluster (in this case CRP1). In 995 both cases, the multivariate model includes age, sex and IBD type as covariates. The dashed vertical 996 lines are used as a reference to indicate no effect.



CRP4

CRP5

Cluster

CRP6

CBP7 CRP8





0%

CRP1 CRP2 CRP3

998 Figure S25. Crohn's disease patients in the Lothian IBD Registry only. (A) For each CRP cluster, 999 panels show the proportion of individuals with smoking behaviour recorded as "no" (no and never) and 1000 yes" (current or previously smoked) at diagnosis respectively. The dashed horizontal line represents? 1001 overall proportions across the entire CRP cohort. (B) Forest plot showing the estimated effect sizes 1002 and associated 95% confidence intervals for smoking: yes versus no (baseline category) in a 1003 multinomial logistic regression model that uses CRP cluster assignment as outcome. Subjects with a 1004 posterior probability of belonging to their assigned cluster greater than 0.5 were considered in addition 1005 to all subjects in the cohort. Effect sizes are with respect to the reference cluster (in this case CRP1).





1009

Α

1010 Figure S26. Crohn's disease patients in the Lothian IBD Registry only. (A) For each CRP cluster, 1011 panels show the proportion of individuals with Montreal Location recorded as L1, L2 and L3 1012 respectively. The dashed horizontal line represents overall proportions across the entire CRP cohort. 1013 (B) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for 1014 Montreal Location: L2 and L3 versus L1 (baseline category) in a multinomial logistic regression model 1015 that uses CRP cluster assignment as outcome. Subjects with a posterior probability of belonging to 1016 their assigned cluster greater than 0.5 were considered in addition to all subjects in the cohort. Effect 1017 sizes are with respect to the reference cluster (in this case CRP1). The multivariate model includes 1018 age, sex, smoking, Montreal location (L1, L2, L3), upper gastrointestinal inflammation (L4), and 1019 Montreal behaviour (B1, B2/B3) as covariates. The dashed vertical lines are used as a reference to 1020 indicate no effect.





1022	Figure S27. Crohn's disease patients in the Lothian IBD Registry only. (A) For each CRP cluster,
1023	panels show the proportion of individuals with Montreal L4 (upper gastrointestinal inflammation),
1024	recorded as present or non present. The dashed horizontal line represents overall proportions across
1025	the entire CRP cohort. (B) Forest plot showing the estimated effect sizes and associated 95%
1026	confidence intervals for L4: present versus not present (baseline category) in a multinomial logistic
1027	regression model that uses CRP cluster assignment as outcome. Subjects with a posterior probability
1028	of belonging to their assigned cluster greater than 0.5 were considered in addition to all subjects in the
1029	cohort. Effect sizes are with respect to the reference cluster (in this case CRP1). The multivariate
1030	model includes age, sex, smoking, Montreal location (L1, L2, L3), upper gastrointestinal inflammation
1031	(L4), and Montreal behaviour (B1, B2/B3) as covariates. The dashed vertical lines are used as a
1032	reference to indicate no effect.





1034	Figure S28. Crohn's disease patients in the Lothian IBD Registry only. (A) For each CRP cluster,
1035	panels show the proportion of individuals with Montreal behaviour recorded as B1 or B2/B3
1036	respectively. The dashed horizontal line represents overall proportions across the entire CRP cohort.
1037	(B) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for
1038	Montreal behaviour: B2/B3 versus B1 (baseline category) in a multinomial logistic regression model
1039	that uses CRP cluster assignment as outcome. Subjects with a posterior probability of belonging to
1040	their assigned cluster greater than 0.5 were considered in addition to all subjects in the cohort. Effect
1041	sizes are with respect to the reference cluster (in this case CRP1). The multivariate model includes
1042	age, sex, smoking, Montreal location (L1, L2, L3), upper gastrointestinal inflammation (L4), and
1043	Montreal behaviour (B1, B2/B3) as covariates. The dashed vertical lines are used as a reference to
1044	indicate no effect.
1045	





1047	Figure S29. Ulcerative colitis patients in the Lothian IBD Registry only. (A) For each CRP cluster,
1048	panels show the proportion of individuals with smoking behaviour recorded as "no" (no and never) and
1049	"yes" (current or previously smoked) at diagnosis respectively. The dashed horizontal line represents
1050	overall proportions across the entire FC cohort. (B) Forest plot showing the estimated effect sizes and
1051	associated 95% confidence intervals for smoking: yes versus no (baseline category) in a multinomial
1052	logistic regression model that uses FC cluster assignment as outcome. Subjects with a posterior
1053	probability of belonging to their assigned cluster greater than 0.5 were considered in addition to all
1054	subjects in the cohort. Effect sizes are with respect to the reference cluster (in this case CRP1). The
1055	multivariate model includes age, sex, smoking and Montreal extent (E1, E2, E3). The dashed vertical
1056	lines are used as a reference to indicate no effect.





1057

1058 Figure S30. Ulcerative colitis patients in the Lothian IBD Registry only only. (A) For each cluster, 1059 panels show the proportion of individuals with Montreal extent recorded as E1, E2 and E3 1060 respectively. The dashed horizontal line represents overall proportions across the entire CRP cohort. 1061 (B) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for 1062 Montreal extent: E2 and E3 versus E1 (baseline category) in a multinomial logistic regression model 1063 that uses FC cluster assignment as outcome. Subjects with a posterior probability of belonging to their 1064 assigned cluster greater than 0.5 were considered in addition to all subjects in the cohort. Effect sizes 1065 are with respect to the reference cluster (in this case CRP1). The multivariate model includes age, 1066 sex, smoking and Montreal extent (E1, E2, E3). The dashed vertical lines are used as a reference to 1067 indicate no effect. 1068



1069

1070 Figure S31. CRP cluster-specific cumulative distribution for first-line advanced therapy prescribing for 1071 Crohn's disease (red) and ulcerative colitis (teal) subjects in (A) the Lothian IBD Registry and (B) 1072 national Danish registry data. Clusters are ordered from lowest (CRP1) to highest (CRP8) cumulative

1073 inflammatory burden. The number of CD and UC subjects present in each cluster is displayed as

1074

panel titles. Curves which would describe fewer than five subjects are not shown.







1076 Figure S32. (A) For each FC cluster in the Lothian IBD Registry, panels show the proportion of 1077 individuals included in the overlap LIBDR cohort, which consists of LIBDR subjects included in both 1078 the FC and CRP analysis. The dashed horizontal line represents overall proportions across the entire 1079 FC cohort. (B) As in (A), but focusing on CRP clusters instead. The dashed horizontal line represents 1080 overall proportions across the entire CRP cohort.

- 1081
- 1082



Figure S33. Comparison between faecal calprotectin (FC) and processed CRP cluster assignment for the Danish cohort. Results are reported based on the overlap cohort, consisting of 5685 subjects included in both the FC and CRP analysis. (A) all subjects; (B) Crohn's disease; and (C) ulcerative colitis. Each segment denotes the size of the cluster whilst the alluvial segments connecting the nodes visualises the number of subjects shared between clusters. 



1092 1093 Figure S34. Prescribing trends over time for Crohn's disease subjects in the Danish faecal 1094 calprotectin cohort for (A) commencement of an advanced therapy, (B) commencement of an 1095 immunomodulator, and (C) a course of corticosteroids (defined as 1500mg total). Subjects are 1096 stratified by FC cluster assignment. For confidentiality reasons, categories with <5 individuals at each 1097 time interval were merged with the category with one fewer treatment. 1098



1099

1100 Figure S35. Prescribing trends over time for ulcerative colitis subjects in the Danish faecal calprotectin 1101 cohort for (A) commencement of an advanced therapy, (B) commencement of an immunomodulator, 1102 and (C) a course of corticosteroids (defined as 1500mg total). Subjects are stratified by FC cluster 1103 assignment. For confidentiality reasons, categories with <5 individuals at each time interval were

1104

merged with the category with one fewer treatment.





1106 Figure S36. Number of surgical bowel resections over time for Crohn's disease subjects in the Danish 1107 cohort. Stratified by faecal calprotectin cluster assignment.



1109 Figure S37. Number of surgical bowel resections over time for ulcerative colitis subjects in the Danish 1110 cohort. Stratified by faecal calprotectin cluster assignment.

# 1111 Supplemental tables

Clusters	Maximum log- likelihood	AIC	BIC
2	-16532-10	33094-20	33168.35
3	-16354-39	32754.78	32868-47
4	-16260-21	32582.42	32735.66
5	-16201.86	32481.71	32674-49
6	-16141.82	32377.63	32609-96
7	-16109.77	32329.54	32601.42
8	-16076-89	32279.77	32591.19
9	-16039.66	32221.33	32572.29
10	-16015-29	32188-59	32579.09

1112

Table S1. Likelihood-based model statistics for LCMMs fitted to faecal calprotectin data across 2–10

1113

clusters using the chosen model specification. Boldface font indicates optimal values.

Clusters	Maximum log- likelihood	AIC	BIC
2	-15451-41	30932.82	31015-57
3	-15314.76	30675.52	30802.40
4	-15240-15	30542.29	30713-30
5	-15173-04	30424.09	30639-23
6	-15106-25	30306.50	30565.78
7	-15051.43	30212.86	30516-27
8	-15016-96	30159.91	30507.45
9	-15014.76	30171.53	30563-20
10	-15014-40	30186-81	30622.61

1114 1115

Table S2. Likelihood-based model statistics for LCMMs fitted to processed CRP data across 2–10 clusters using the chosen model specification. Boldface font indicates optimal values.

# Supplementary material for Constantine-Cooke and Vestergaard et al.

Nathan Constantine-Cooke<sup>1, 2</sup>, Marie Vibeke Vestergaard<sup>3</sup>, Karla Monterrubio-Gómez<sup>1, 2</sup>, and Catalina A. Vallejos<sup>2</sup>

 $^{1}$ Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK

<sup>2</sup>MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK

<sup>3</sup>Center for Molecular Prediction of Inflammatory Bowel Disease, PREDICT, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark

# Supplemental Note 1: Data definitions

## 1.1 Lothian IBD Registry

### Additional phenotyping (at diagnosis)

When available, additional phenotyping information (at diagnosis) was manually extrated by the clinical team from electronic healthcare records (TrakCare; InterSystems, Cambridge, MA). For CD subjects, the following information was extracted:

- **Smoking**: recorded as a binary (yes/no) variable.
- Montreal location:
  - L1 (Ileal): limited to the ileum, the final segment of the small intestine.
  - L2 (Colonic): limited to the colon/large intestine.
  - L3 (Ileocolonic): inflammation is present in both the ileum and colon.
- Montreal behaviour:
  - B1 (Inflammatory): non-stricturing and non-penetrating
  - B2 (Stricturing): where the formation of fibrosis leads to the narrowing of the intestine.
  - B3 (Penetrating): where the inflammation causes the formation of fistulas or abscesses.

Due to small numbers, B2 and B3 are merged into a single group (complicated CD) when analysing Montreal behaviour.

- Upper GI inflammation (L4): whether any gastrointestinal inflammation is detected further up than the ileum. Usually, upper inflammation is considered a modifier for Montreal location. Recorded as a binary (yes/no) variable. L4 was missing for a high proportion of subjects. This is because the required investigations are only carried out where upper GI inflammation is suspected. As such, we have manually mapped missing L4 values as "No" (i.e. no upper GI inflammation for the associated patients).
- **Perianal disease**: considered a modifier for Montreal behaviour and is a severe complication of Crohn's disease involving inflammation around the anus. Recorded as a binary (yes/no) variable.

For UC subjects, the following additional phenotyping information was considered:

• Smoking: recorded as a binary (yes/no) variable.

## • Montreal extent:

- E1 (Ulcerative proctitis): limited to the rectum.
- E2 (left sided colitis): inflammation is present in the rectum, the sigmoid colon, and possibly the descending colon.
- E3 (extensive colitis): inflammation extends beyond the splenic flexure.

## List of advanced therapies relevant for IBD management

The following biologics and small molecules were considered to be advanced therapies relevant for the treatment of IBD. All other advanced therapies were ignored. If one of these advanced therapies were prescribed for a condition other than IBD, for example for rheumatoid arthritis, then these treatments were still considered given they are known to modify IBD outcomes. Only prescriptions given within the observation period (seven years since diagnosis) were considered.

- Adalimumab
- Certolizumab
- Golimumab
- Infliximab
- Risankizumab
- Tofacitinib
- Upadacitinib
- Ustekinumab
- Vedolizumab

# 1.2 National Danish registry data

## **Diagnosis adjudication**

Subjects with IBD were defined as either

- 1. Having two different secondary care interactions linked to an ICD-10 IBD code (see Table 1.2) within a two year period, and/or
- 2. Two inpatient interactions assigned an IBD code (no period requirement).

If a subject meets only the first criterion, the first IBD secondary care interaction is used as the date of diagnosis. If a subject only meets the second criterion, then the date of the first inpatient record is used. If a patient meets both criteria, the earliest date is used.

Patients were assigned an IBD subtype (either CD or UC) based on the majority of the ICD-10 codes. If there were an equal number of IBD subtype diagnoses, the latest diagnosis was used.

Table 1.2 details the registry and codes used to obtain the data for each of the variables used in the Danish component of the study.

#### Prescribing and surgery data

As additional prescribing data were available for the Danish cohort, plots exploring these data were produced. Advanced therapy and immunomodulator plots were generated as the cumulative number of unique treatments over time for each patient. For systemic corticosteroids, one treatment course was defined as 1500 mg with the cumulative number of treatment courses plotted. For major surgeries related to IBD, the cumulative number of surgeries were plotted. For confidentiality reasons, categories with < 5 individuals in at each time interval were merged with the category with one fewer treatment.
Variable	Definition and codes	Source
IBD-related hospital interactions Biochemistry tests	ICD-10: K50, K51	Danish National Patient Reg- istry The Danish nationwide Regis- ter of Laboratory Results for Research
CRP	NPU: NPU19748	
Fecal calprotectin	NPU: NPU19717, NPU26814	
Biologic therapies		Danish National Prescription
and small molecules		Registry
Infliximab	C_OPR: BOHJ18A1/	
	BOHJ18A	
Adalimumab	C_OPR: BOHJ18A3	
Ustekinumab	C-OPR: BOHJ18B3	
Vedolizumab	C ODD, DOH 196	
Cortolizumah	$C_{\rm OPD}$ , $BOH_{18A5}$	
Colimumah	C OPB: BOH I18A4	
Risankizumah	C OPB: BOHJ19N1	
Tofacitinib	C OPR: BOHJ28D	
Upadacitinib	C OPR: BWHP107	
Immunomodulators		Danish National Prescription
		Registry
Azathioprine	ATC: L04AX01; C_OPR: BWHB83	
Mercaptopurine	ATC: L01BB02	
Methotrexate	ATC: L04AX03/L01BA01; C_OPR: BWHA115	
Systemic corticos-	ATC: H02AB01, H02AB02,	Danish National Prescription
teroids	H02AB04, H02AB06,	Registry
	H02AB07, H02AB08,	
	H02AB09	
IBD-related major		Danish National Patient Reg-
surgery		istry
Intestinal resections	NCSP: KJGB, KJFB (excl. KJFB10+13)	
Enteroenterostomy	NCSP: KJFC	
Enterostomy	NCSP: KJFF	
Colectomy	NCSP: KJFH	
Intestinal stricture-	NCSP: KJFA60, KJFA61,	
plasty	KJFA63 NGSD, KIEAOC, KIEAOZ	
Surgery	NCSP: KJFA96, KJFA97	
Other intestinal surgery	NCSP: KJFW	
Stenosis surgery with-		
Out	NCSD. KIEI	
resection of adhesiolysis	NOOL: VILT	

Table 1.1: For each variable used in the Danish analyses, the corresponding registry and codes used to obtain the data.

## Supplemental Note 2: Processing of CRP measurements

Further processing was applied to CRP data to smooth out short-term fluctuations. In the LIBDR, measurements were grouped into intervals of t: [0, 0.5), [0.5, 1.5), [1.5, 2.5), [0.5, 1. $[2\cdot5, 3\cdot5), [3\cdot5, 4\cdot5), [4\cdot5, 5\cdot5), [5\cdot5, 7],$  where t = 0 (years) is the time of diagnosis. The median CRP for each interval was calculated for each subject and used as input for subsequent analyses. The centre of each interval was used as the corresponding observation time. The same approach was used for the Danish data, however intervals of t: [0, 0.5), [0.5, 1.5), [1.5, 2.5), [2.5, 3.5), [3.5, 5] were used instead to take into account the differences in follow-up between the cohorts.

## Supplemental Note 3: Latent class mixed model

### Introduction

This note provides a formal definition of latent class mixed models (LCMMs)<sup>1</sup> and describes how the most appropriate model specifications were found.

All models were fit using the lcmm R package. In all cases, models were fit using a maximum of 24,000 Marquardt iterations and all other options left at the default settings. An automatic grid search approach with 50 repetitions was used to attempt to avoid local maxima. All models converged as per default convergence criteria.

### Formal definitions

The LCMM consists of two sub-models. A longitudinal sub-model and a class assignment sub-model. The former will be introduced before the latter.

#### Longitudinal sub-model

We assume a population of N individuals is heterogeneous and composed of G latent classes (or clusters): each characterised by a distinct mean profile of a marker of disease activity (in logarithmic scale) across time. We assume each subject i has a vector of repeated measurements of length  $n_i$ , allowing the number of measurements to differ across subjects. A random effects specification is used to capture intra-individual correlation in measurements. We allow each subject i to belong to only one latent class and introduce a discrete random variable  $c_i$  which is equal to q if subject i belongs to the latent class g, where  $g = 1, \ldots, G$ .

The logarithm of the biomarker measurement (FC or CRP) for the *i*th subject taken at time  $t_{ij}$  is denoted by  $Y_{ij}$ . Given that the subject *i* belongs to class *g*, the latter is modelled using a latent class mixed model LCMM:

$$Y_{ij}|_{c_i=g} = \mathbf{X}(t_{ij})'\beta_g + u_{ig} + \epsilon_{ij}$$
(3.1)

where the vector of regression coefficients  $\beta_q$  capture class-specific fixed effects,  $u_{iq}$  denote random effects distributed such that  $u_{ig} \sim \mathcal{N}(0, \sigma_u^2)$  (we assume the variance  $\sigma_u^2$  is shared across classes, but a more general form of the model allows for class-specific variance). In our analysis, we assume a single random effect (intercept)  $u_{iq}$  to account for correlation between longitudinal observations collected for the same individual. Finally,  $\epsilon_{ij}$  indicates an independently distributed Gaussian error term with zero mean and variance  $\sigma_{\epsilon}^2$ .

#### Class membership sub-model

The probability of  $c_i = g$  is given as a class-specific probability and is described by a multinomial logistic model:

$$P(c_i = g) = \frac{e^{\mathbf{X}_{ci}^{\top}\xi_g}}{\sum_{l=1}^{G} e^{\mathbf{X}_{ci}^{\top}\xi_g}},$$
(3.2)

where  $\mathbf{X}_{ci}$  is a vector of covariates and  $\xi_g$  is a vector of parameters whose first element corresponds to a class-specific intercept. For identifiability, the intercept associated to class G is assumed to be equal to zero. Note that the covariates in Equation (3.2) do not need to match those used in the longitudinal model. In our analysis, IBD type (CD, UC or IBDU for the LIBDR cohort; CD or UC for the Danish data) was included as a covariate in this model.

#### Posterior probabilities of class assignment

After inferring all model parameters, posterior class-membership probabilities for each subject are given by:

$$\hat{\pi}_{ig}^{Y} = P(c_i = g | \mathbf{Y}_i, \mathbf{X}(t_i), \hat{\theta}_G) = \frac{\hat{\pi}_{ig} \phi_{ig}(\mathbf{Y}_i | c_i = g, \theta_G)}{\sum_{l=1}^G \hat{\pi}_{il} \phi_{il}(\mathbf{Y}_i | c_i = l, \hat{\theta}_G)}$$
(3.3)

where  $\mathbf{Y}_i$  denotes a vector of length  $n_i$  containing all longitudinal measurements recorded for subject i,  $\mathbf{X}(t_i)$  is a matrix  $(n_i \times 4)$  comprised of all the corresponding time-dependent covariates for subject  $i, \theta_G$  denotes the estimates obtained for all model parameters  $(\beta_1, \ldots, \beta_G, \sigma_u^2, \sigma_\epsilon^2, \xi_1, \ldots, \xi_G)$  and  $\hat{\pi}_{ig}$  corresponds to Equation (3.2) evaluated on  $\hat{\theta}_G$ . Finally,  $\phi_{ig}(\mathbf{Y}_i|c_i = g, \hat{\theta}_G)$  denotes a multivariate normal density function with mean  $\mathbf{X}(t_i)\hat{\beta}_g$  and variance covariance  $\sigma_u^2 \mathbf{X}(t_i) \mathbf{X}(t_i)' + \hat{\sigma}_{\epsilon}^2 I_{n_i}$ , where  $I_{n_i}$  denotes an identify matrix with dimension  $n_i$ .

#### Fixed effects specified as natural cubic splines

The vector of time-dependent covariates  $\mathbf{X}(t)$  (see Equation (3.1)) was defined using an intercept term and natural cubic splines  $(NCS)^2$  to capture non-linear dependency between observations and time. The NCS were calculated as a pre-processing step prior to estimating the model in Equation (3.1) using the ns() function of the splines R library<sup>3</sup>. Knots were located at quantiles of measurement times across all measurements.

To determine the most appropriate number of interior knots for the LIBDR cohort, LCMMs with six clusters were fitted to the LIBDR FC data assuming two to four knots. Visual inspection, Akaike information criterion (AIC), and Bayesian information criterion (BIC) were used to determine the most appropriate NCS specification, which was then used to fit the models used in the main analysis.

The optimal AIC was reported for the NCS model with four interior knots whilst BIC favoured the three-knot specification (Table 3.1). However, visual inspection of the

four-knot specification appeared to result in overfitting of the data (Figure 3.1). As such, the three-knot approach was used to specify the fixed effects of the longitudinal sub-model for all further FC and CRP modelling in the LIBDR cohort. As such, the time-dependent covarite vector was defined as  $\mathbf{X}(t) = (1, X_1(t), X_2(t), X_3(t), X_4(t))'$  (the first element ensures the model includes an intercept term).

A similar approach was used to define the number of knots when analysing the Danish data. Two knots were chosen for both FC and CRP analyses.

Specification	Maximum log-likelihood	AIC	BIC
2 Knots	-19766.31	39614.61	39823.41
3 Knots	-19615.33	39324.67	39564.02
4 Knots	-19604.65	39315.30	39585.21

Table 3.1: Likelihood-based model statistics for LCMMs assuming six clusters with varying specifications for the fixed effects of the longitudinal sub-model. The models considered used natural cubic splines with varying knots. Boldface font indicates optimal values.





Figure 3.1: Cluster trajectories of FC for a LCMM using natural cubic splines with 4 knots. Vertical teal lines indicate knot locations. Dotted horizontal lines indicate  $\log(250\mu g/g)$  FC which is commonly used as a cutoff for disease activity.

## **Supplemental Note 4: Software versions**

As LIBDR and Danish analyses were conducted on separate computational platforms, the software versions differed.

### 4.1 Lothian IBD Registry

R (v.  $4\cdot4\cdot2$ ),<sup>3</sup> extended using the lcmm (v.  $2\cdot1\cdot0$ ),<sup>1</sup> ggalluvial (v.  $0\cdot12\cdot5$ ),<sup>4</sup> nnet (v.  $7\cdot 3-19$ ),<sup>5</sup> and datefix R (v.1 $\cdot 7\cdot 0$ )<sup>6</sup> packages, was used. Analytical reports have been generated using the Quarto scientific publishing system (v.1.4.551) and are hosted online (https://vallejosgroup.github.io/IBD-Inflammatory-Patterns/). An R package, libdr (v.1.1.0), has also been produced, supporting the reuse of our R code with other datasets.

## 4.2 National Danish registry data

R (v. 4.4.0) extended using the lcmm (2.1.0), ggalluvial 0.12.5, and nnet 7.3.19 packages was used for the Danish analyses. The R code is shared in the VallejosGroup/IBD-Inflammatory-Patterns GitHub repository under the source/dk directory.

# Bibliography

- Proust-Lima C, Philipps V, Liquet B. Estimation of extended mixed models using latent classes and latent processes: The R package lcmm. J Stat Softw 2017; 78(2): 1–56. doi: 10.18637/jss.v078.i02
- [2] Hastie T, Tibshirani R, Friedman J. The Elements of Statistical Learning. Springer Series in StatisticsNew York, NY: Springer. 2009
- [3] R Core Team . R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing . 2022.
- [4] Brunson JC. ggalluvial: layered grammar for alluvial plots. J Open Source Softw 2020; 5(49): 2017. doi: 10.21105/joss.02017
- [5] Venables WN, Ripley BD. *Modern applied statistics with S.* New York: Springer. fourth ed. 2002.
- [6] Constantine-Cooke N. datefixR: fix really messy dates in R. https://CRAN.Rproject.org/package=datefixR; 2024